Chemistry, lung health, temperature science, carcinogen data, EVALI facts, cost analysis — everything you need to make an informed choice.
The debate between vaping and smoking cannabis sits at the intersection of chemistry, medicine, personal preference, and economics. This guide cuts through the anecdote and ideology to provide a science-based comparison of both methods — what actually happens chemically, what the peer-reviewed literature says about respiratory health, and which method is likely to serve you best depending on your goals and situation.
The core difference between smoking and vaping is thermochemical: it is a question of what happens to plant material under different thermal conditions.
When cannabis is smoked, a flame heats the material to between 800 and 900°C at the burning tip (the cherry). At these temperatures, the organic plant matter undergoes pyrolysis — the thermal decomposition of organic compounds in the absence of full oxygen — producing a complex mixture of over 2,000 identified chemical compounds. Most of the psychoactive THC and aromatic terpenes are destroyed instantly in the combustion zone. What reaches the lungs is a combination of unburned and partially burned compounds plus a wide spectrum of combustion byproducts.
Key toxic compounds produced by cannabis combustion include:
A vaporizer heats cannabis to 160–220°C, hot enough to volatilize THC, CBD, and terpenes (which have boiling points in this range) but well below the ignition temperature of plant matter (~230°C+). The result is a vapor containing mostly cannabinoids and terpenes, with dramatically fewer combustion byproducts. Multiple studies have detected measurably lower concentrations of CO, PAHs, and other toxicants in vapor compared to smoke from the same cannabis material. One widely cited study (Gieringer et al., Harm Reduction Journal) found that the cannabinoid-to-tar ratio in vapor was approximately 5–10× higher than in smoke, meaning users consume far fewer byproducts per unit of THC absorbed.
Temperature control is the defining technical advantage of dry herb vaporizers. Different cannabinoids and terpenes have distinct boiling points, and the temperature you vape at determines your experience profile.
| Temperature Range | Experience Profile | Key Compounds Active | Notes |
|---|---|---|---|
| 160–175°C | Light, clear-headed, functional | CBD, limonene, β-caryophyllene, early THC | Best terpene flavor; ideal for daytime use |
| 175–195°C | Balanced, moderate high | THC (peak), myrcene, linalool | Most popular range; good THC:byproduct ratio |
| 195–210°C | Strong, sedating, heavier vapor | CBN (from THC degradation), α-terpineol | More byproducts start forming; harsher on throat |
| 210–220°C | Very strong, indica-like sedation | High CBN, reduced terpenes | Approaching combustion zone; not recommended |
| >230°C | Combustion begins | Smoke compounds form | Equivalent to smoking at lower intensities |
| 800–900°C | Full combustion (smoking) | 2,000+ compounds including PAHs | Cannabis joint burning tip temperature |
The carcinogenicity of cannabis smoke has been the subject of debate, in part because the epidemiological evidence for cannabis-specific lung cancer risk is less clear than for tobacco — likely due to confounding factors including lower average total cannabis consumption volumes compared to daily tobacco smoking. However, the chemical toxicology is not in doubt: cannabis smoke contains the same carcinogen classes as tobacco smoke.
| Compound / Category | Present in Smoke? | Present in Vapor? | Health Relevance |
|---|---|---|---|
| Benzo[a]pyrene (PAH) | Yes (significant) | Trace/undetectable | Group 1 carcinogen (IARC) |
| Carbon Monoxide (CO) | Yes (high levels) | Negligible | Cardiovascular stress, reduces O₂ delivery |
| Benzene | Yes | Very low | Group 1 carcinogen; leukemia risk |
| Hydrogen Cyanide | Yes | Not detected | Ciliotoxic; impairs lung self-cleaning |
| Tar / Particulate Matter | Yes | Dramatically reduced | Causes chronic bronchitis, mucus production |
| Ammonia | Yes (cannabis smoke has higher ammonia than tobacco) | Very low | Airway irritant; damages cilia |
| THC | Yes (25–30% bioavailable) | Yes (55–75% bioavailable) | Primary intended compound |
| Terpenes (intact) | Most destroyed by combustion | Well preserved at <185°C | Flavor, entourage effect |
The research literature on cannabis vaping and lung health is still developing, but several key studies and systematic reviews are informative:
Tobacco smoke comparison: Multiple studies confirm that cannabis smoke causes bronchitis symptoms, wheezing, and increased phlegm production in regular smokers — effects consistent with the known airway irritants in cannabis smoke. These effects are similar in mechanism (though not identical in magnitude) to tobacco smoke.
Vaporizer studies: A well-cited study by Earleywine and Barnwell (2007) found that cannabis users who switched to vaporizers reported significant reductions in respiratory symptoms including cough, phlegm, and wheezing, even after controlling for total cannabis consumption. The effect was particularly strong in those who had previously been heavy smokers.
UCSF study (Abrams et al.): Researchers found that vaporization delivered equivalent cannabinoid blood plasma levels to smoking while producing measurably lower carbon monoxide levels in exhaled breath, confirming reduced combustion product intake without sacrificing efficacy.
Long-term population data: The large-scale CARDIA study (Pletcher et al., 2012) found that low-to-moderate cannabis smoking was not associated with decline in lung function measured by FEV1/FVC ratios, whereas heavy use was correlated with some impairment. This paradox — that light cannabis smoking may not cause measurable spirometric decline — is thought to be due to the lower average total volume of cannabis smoked compared to tobacco, and to the deep inhalation technique which may actually exercise respiratory muscles. However, this does not apply to heavy daily users, and none of these findings argue against the toxicological benefits of avoiding combustion.
The EVALI (e-cigarette or vaping product use-associated lung injury) outbreak alarmed health authorities worldwide and remains an important reference point in vaping discussions. It is critical to understand the actual cause of this outbreak before using it to evaluate cannabis vaping risks in general.
The CDC’s investigation of over 2,800 hospitalized cases identified vitamin E acetate — a thick, oily substance used as a cutting and thickening agent in illicit THC vape cartridges — as the primary driver of lung injury in the vast majority of EVALI cases. Vitamin E acetate was detected in bronchoalveolar lavage fluid from 94% of EVALI patients tested in one study. When inhaled, this compound interferes with lung surfactant and causes lipoid pneumonia-like injury.
This outbreak was overwhelmingly concentrated in users of black market, counterfeit, or unregulated THC cartridges. Licensed cannabis dispensaries operating under regulated manufacturing standards do not use vitamin E acetate or similar adulterants. Dry herb vaporizers, which heat actual cannabis flower rather than oil cartridges, were not implicated in EVALI cases.
Takeaway: EVALI is a real risk from illicit or unregulated vape cartridges. It is not a meaningful risk when using regulated products purchased from licensed dispensaries, or when using dry herb vaporizers with tested cannabis flower.
One area where vaporization has an undisputed advantage over smoking is the preservation of terpenes — the aromatic compounds responsible for cannabis’s wide spectrum of flavors and potentially contributing to its therapeutic effects via the entourage effect.
Terpenes are volatile compounds that begin evaporating at relatively low temperatures (limonene boils at 176°C, myrcene at 167°C, linalool at 198°C). Combustion at 800–900°C instantly destroys the majority of terpenes, turning their chemical structures into simpler, often acrid compounds. This is why cannabis smoke has a harsh, burnt smell that bears little resemblance to the flower’s natural aroma.
Vaporization at 165–185°C captures these terpenes at or near their boiling points, producing vapor that expresses the strain’s unique aromatic profile. Experienced vapers report being able to taste distinct terp profiles — citrus from Limonene-dominant strains, pine from α-pinene-heavy cultivars, tropical fruit from Myrcene and Terpinolene combinations. This is essentially impossible to replicate when smoking.
Vapor from a vaporizer dissipates significantly faster than smoke and produces much less lingering odor. In cannabis-tolerant indoor environments, this is a meaningful practical advantage. The smell from a dry herb vaporizer at optimal temperatures is present but dissipates within minutes; the smell from smoking can linger for hours and penetrates fabrics, hair, and surfaces.
However, "discreet" does not mean "odorless" — vapor at higher temperatures can still be quite pungent, and some portable vaporizers produce visible plumes that are easily recognizable. The discretion advantage of vaping is real but contextual.
| Cost Factor | Smoking | Vaping (Dry Herb) |
|---|---|---|
| Initial equipment cost | $5–50 (papers, pipe, bong) | $80–600+ (quality vaporizer) |
| Cannabis used per session | 0.3–0.7g (typical joint) | 0.1–0.3g (bowl in vaporizer) |
| THC extraction efficiency | 25–30% | 50–80% |
| Sidestream waste | High (joint continues burning between puffs) | None (no combustion between draws) |
| Reuse of spent material (AVB) | No (ash) | Yes — AVB (Already Vaped Bud) still contains cannabinoids and can be eaten or used in edibles |
| Annual cannabis cost (est., 1g/day user) | $1,460–3,650 | $730–1,825 (approx. 50% less cannabis needed) |
| Break-even point (mid-range vaporizer) | — | Approximately 2–4 months of regular use |
One notable added benefit of dry herb vaping is AVB (Already Vaped Bud). The spent material from a vaporizer is not ash — it still contains residual cannabinoids, typically 10–30% of the original THC content depending on vaporization temperature and duration. AVB can be eaten directly (it is already decarboxylated from the vaping process), mixed into food, or used to make cannabutter. This provides a genuine secondary return on investment unavailable to smokers.
Not all vaporizers are equivalent. Understanding the main categories helps when making a purchase decision:
For someone new to cannabis, vaping at a controlled temperature (start at 170–180°C) offers significant advantages: more predictable onset, less harsh on the lungs, better flavor, and easier dose control. The delayed response in some vaporizers (about 30 seconds to heat up vs. immediate combustion) also provides a natural "slow down" that helps beginners avoid overconsumption.
Smoking is more forgiving technically — you cannot set the wrong temperature — but the lack of dose control and the harsher smoke experience make it less ideal for first-time users. If you choose to smoke, small, controlled puffs with full exhalation are recommended over deep breath-holds, which do not meaningfully increase cannabinoid absorption but do increase exposure to toxicants.